Storage Lesion • Miscellaneous • Patient Outcomes • Pediatrics • Surgical Techniques • Transfusion Practice • Transfusion Risks /
Adverse Events
To improve patient outcomes through optimal blood management. Blood management is the appropriate provision and use of blood, its components and derivatives, and strategies to reduce or avoid the need for a blood transfusion.
Intraoperative Allogeneic Red Blood Cell Transfusion in Ampullary Cancer Outcome after Curative Pancreatoduodenectomy: A Clinical Study and Meta-Analysis
Posted: August 5, 2008 
based on 1 reader · Rate this article
Outcome Analysis of Blood Product Transfusion in Trauma Patients: A Prospective, Risk-Adjusted Study
Posted: August 5, 2008 based on 2 readers · Rate this article
Erythropoietin and Granulocyte-Colony Stimulating Factor Treatment Associated With Improved Survival in Myelodysplastic Syndrome
Posted: July 29, 2008 based on 1 reader · Rate this article
For more articles, click here
Online Resources Regarding Erythropoiesis Stimulating Agents (ESAs)
Posted: August 1, 2008
The Joint Commission - Blood Management Performance Measures Project Update
Posted: July 21, 2008
SABM 2008 Regional Cancun Blood Management Conference
Posted: July 11, 2008
For more Society news, click here
U.S. News & World Report - Washington, DC, USA
More than 44,000 Vials of Procrit Recalled
Newsinferno.com - New York, NY, USA
Comments requested on Joint Commission meeting to determine the need to incorporate blood management performance measures into their survey and accreditation process
CBBS e-Network Forum - Sacramento, CA, USA
Erythropoietin Accelerates Functional Recovery After Peripheral Nerve Injury
Journal of Bone and Joint Surgery (subscription) - USA
Blood Management Summit
Cleveland Clinic - Cleveland, OH, USA
FDA orders labeling changes for ESAs
HemOncToday - Thorofare, NJ, USA
Amgen Issues Statement in Response to Revised ESA Labeling Received from the FDA Today
Amgen - Thousand Oaks, CA, USA (Press Release)
Follow Up to the January 3, 2008 Communication About an Ongoing Safety Review Erythropoiesis-Stimulating Agents (ESAs) Epoetin alfa (marketed as Procrit, Epogen) Darbepoetin alfa (marketed as Aranesp)
U.S. Food and Drug Administration (FDA)
For more eHeadlines, click here
